Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02809690 · ClinicalTrials.gov registry record · Phase 1
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02809690 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 18 participants.
The verdict
NCT02809690, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Multiparametric Magnetic Resonance Imaging
- DEVICE Positron Emission Tomography
- DRUG 18F-FMAU
- DEVICE CAT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09-12 |
| Est. Completion | 2021-07-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02809690
The ClinicalTrials.gov registry entry for NCT02809690 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02809690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02809690 about?
NCT02809690 is a clinical study titled "18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer". This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vei...
What is the current status of trial NCT02809690?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-09-12. Estimated completion is 2021-07-21.
What interventions are being tested in trial NCT02809690?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Multiparametric Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (DEVICE), 18F-FMAU (DRUG), CAT (DEVICE).
Who is sponsoring clinical trial NCT02809690?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.